Every percentage, competitor price, and clinical claim on thriveaxis.org points back to a verifiable primary source. This page catalogs those sources so you, your provider, or a regulator can verify each one directly. Last full refresh: 2026-04-24.
| Trial | Medication studied | Primary finding we cite | Citation |
|---|---|---|---|
| STEP-1 | Branded semaglutide 2.4 mg (Wegovy®) | Mean body-weight reduction of −14.9% vs. −2.4% placebo over 68 weeks in adults with overweight/obesity | Wilding JPH et al. N Engl J Med 2021;384:989-1002. DOI: 10.1056/NEJMoa2032183 · NCT03548935 |
| SURMOUNT-1 | Branded tirzepatide 5/10/15 mg (Zepbound®) | Mean body-weight reduction up to −20.9% at 15 mg vs. −3.1% placebo over 72 weeks in adults with obesity without diabetes | Jastreboff AM et al. N Engl J Med 2022;387:205-216. DOI: 10.1056/NEJMoa2206038 · NCT04184622 |
| SELECT | Branded semaglutide 2.4 mg | 20% reduction in 3-point MACE (CV death, non-fatal MI, non-fatal stroke) in adults with established CVD and overweight/obesity without diabetes | Lincoff AM et al. N Engl J Med 2023;389:2221-2232. DOI: 10.1056/NEJMoa2307563 · NCT03574597 |
All three RCTs evaluated the branded FDA-approved products. ThriveAxis does not claim that compounded semaglutide or compounded tirzepatide produce identical results.
| Source | Relevance to ThriveAxis protocols | Citation |
|---|---|---|
| TRAVERSE Trial | Cardiovascular-safety of testosterone therapy in middle-aged and older men with hypogonadism and pre-existing CV disease or high CV risk. Testosterone non-inferior to placebo for MACE. | Lincoff AM et al. N Engl J Med 2023;389:107-117. DOI: 10.1056/NEJMoa2215025 · NCT03518034 |
| Testosterone meta-analysis (JAMA 2020) | Pooled analysis of testosterone-therapy outcomes on body composition, mood, sexual function, and bone density in men with clinically documented hypogonadism. | Diem SJ et al. Ann Intern Med/JAMA 2020 (systematic review cited in AUA 2018 guideline updates). Testosterone is a DEA Schedule III controlled substance (DEA schedules). Prescribing requires Ryan Haight Act-compliant evaluation by a DEA-registered, state-licensed provider. |
ThriveAxis BHRT protocols reference bio-identical estradiol and progesterone formulations. Supporting evidence includes:
Every peptide referenced on thriveaxis.org falls into one of three regulatory categories. ThriveAxis does not dispense research-only peptides.
| Peptide | Status | ThriveAxis posture |
|---|---|---|
| Semaglutide | FDA-approved (Wegovy/Ozempic); compounded under 503A subject to FDA enforcement discretion | Dispensable via licensed 503A pharmacy when clinically appropriate |
| Tirzepatide | FDA-approved (Zepbound/Mounjaro); FDA ended tirzepatide shortage enforcement discretion 2024–2025 | Availability depends on current FDA posture; provider advises at consult |
| BPC-157, Sermorelin, CJC-1295, Ipamorelin, Tesamorelin | Compounded under 503A when on current FDA bulk-substances category 1 list | Dispensable subject to provider determination and current FDA bulk-list status |
| Orforglipron (Foundayo™) | FDA-approved for chronic weight management (April 1, 2026); first oral small-molecule GLP-1 receptor agonist (FDA approvals) | Prescribable when clinically appropriate per provider determination |
| Retatrutide, MOTS-c, Epithalon, BPC-157 (category status varies) | Investigational or research-stage — not FDA-approved for any indication as of retrieval date | Not dispensed as investigational. Educational content only. No anti-aging, mortality-reduction, or lifespan-extension claims made. BPC-157 status is re-verified on FDA bulk-substances list at each audit. |
Peptide classifications are current as of the retrieval date above and are verified against the FDA bulk-substances list at each audit.
All competitor pricing and feature-availability statements on thriveaxis.org were captured on 2026-04-24 from the competitor's live public-facing marketing site. Competitor offerings change frequently. Where pricing tiers are stepped (e.g., intro offer vs. ongoing), we cite the ongoing price and note the intro pricing.
| Competitor | URL captured | Pricing we cite |
|---|---|---|
| Hims / Hims & Hers | hims.com/weight-loss | $39 intro first month → $199/mo ongoing injectable GLP-1; enclomiphene marketed as "testosterone support," not TRT |
| Ro | ro.co/weight-loss | $39 first-month intro → $74–$149/mo membership + medication ($149–$299 Wegovy pill, $299–$449 Zepbound) |
| Medvi | medviwellness.com | $179 first month intro → $299/mo medication refill + $99 membership after month one |
Any named member, photograph, direct quote, or specific outcome published on thriveaxis.org is published only after the member has signed a HIPAA-compliant written authorization (45 CFR §164.508) covering the specific use of their story. Individual results are not typical and are not guaranteed; outcomes depend on adherence, protocol, baseline metabolic state, and individual response. Where a specific numeric outcome is shown (e.g., pounds lost, body-fat percentage), it is accompanied by an individual-result and typical-results disclosure consistent with the FTC Endorsement Guides.
ThriveAxis operates to a 4-8 hour response-time standard during business hours for provider messaging, and a target of under 48 hours from completed assessment to treatment plan. Response-time standards are tracked internally via the patient portal and reviewed with providers. Aggregate p50/p90 metrics will be published quarterly beginning with the Q2 2026 report (expected release July 2026). Member-specific questions about your own care timeline should be directed to your provider via the portal. Compliance questions: compliance@thriveaxis.org.
Where ThriveAxis copy references "many telehealth platforms" or draws comparisons to other services, our comparator set as of Q4 2025 comprises: Hims & Hers (hims.com, forhers.com), Ro (ro.co, including Ro Body and Ro Pharmacy), Medvi Wellness (medviwellness.com), Henry Meds (henrymeds.com), Marek Health (marekhealth.com), and Defy Medical (defymedical.com). Comparative claims about service scope, accountability tools, dosing education, and pricing are based on retrieval of these services' public-facing websites and published pricing pages in Q4 2025 and are re-verified quarterly. Specific claims cited against individual competitors include a retrieval date inline where used.
Every provider who joins the ThriveAxis network is required to (a) hold an active, unrestricted state medical/advanced-practice license in each state where they see ThriveAxis patients, verified against the state licensing authority's primary records before first patient contact; (b) maintain board certification in internal medicine, family medicine, emergency medicine, urology, endocrinology, or a closely related specialty, verified against ABMS/AOA primary sources where applicable; (c) clear a National Practitioner Data Bank (NPDB) query and state-medical-board disciplinary-action check; and (d) undergo annual re-credentialing including license-renewal verification and updated NPDB query. Operational credentialing packet (SOP document, provider roster with primary-source verifications, query logs) is maintained internally and made available to regulators on request. Head of Compliance & Clinical Standards Michael Harrington, MD oversees the credentialing framework.
ThriveAxis membership pricing is published on /pricing. Prices shown for compounded medications (e.g., compounded semaglutide $150-$350) reflect typical self-pay ranges across our partner 503A compounding pharmacies as of Q1 2026; individual pricing varies by dose and current pharmacy contract. Total-cost estimates (e.g., "~$409/month Optimizer total") are illustrative and assume annual-plan pricing plus one representative compounded protocol; actual monthly totals depend on the specific medications prescribed. Comparative market references (e.g., "local endocrinologist $200-400/visit") are based on a Q4 2025 review of published self-pay pricing for office-based endocrinology and men's-health specialty visits in major U.S. metropolitan markets; local pricing varies significantly by region and we re-verify market ranges quarterly. Competitor pricing references cite the competitor's own published pricing page at the time of retrieval.
As of the retrieval date above, the FDA-approved brand names in the GLP-1/GIP-agonist class include: Wegovy® (semaglutide injection, weight management), Wegovy® oral (semaglutide 25 mg tablet, FDA-approved December 22, 2025 for weight management), Zepbound® (tirzepatide injection, weight management), Saxenda® (liraglutide injection, weight management), Foundayo™ (orforglipron, first oral small-molecule GLP-1 agonist — FDA-approved April 1, 2026 for weight management), Ozempic® (semaglutide injection, type-2 diabetes), Mounjaro® (tirzepatide injection, type-2 diabetes), Rybelsus® (oral semaglutide, type-2 diabetes), Trulicity® (dulaglutide, type-2 diabetes), Victoza® / Byetta® / Bydureon® / Adlyxin® (older-generation agonists, type-2 diabetes). Hero stats on thriveaxis.org cite brand counts for weight-management-indicated products only. Source: FDA Drugs news & approvals; re-verified each audit.
Epidemiological references used on our TRT content pages:
The 60-70% weight-regain-within-one-year figure cited in our GLP-1 FAQ is consistent with the STEP-1 extension and STEP-4 trial data:
Individual outcomes depend on post-treatment lifestyle, presence of ongoing nutrition/fitness/behavioral support, baseline metabolic state, and the tapering protocol used.
ThriveAxis architectural posture on third-party security certifications:
Email compliance@thriveaxis.org with the page URL and the specific claim. We respond within five business days with either the verifying primary source or a correction.